Evidence map›Paper›PMID 37629245›Full record

ArticleJournal of clinical medicine2023

Inadvertent Administration of 72 µg of Follitropin-Δ for Three Consecutive Days Does Not Appear to Be Dangerous for Poor Responders: A Case Series.

Giorgio Maria Baldini, Antonella Mastrorocco, Romualdo Sciorio, Simone Palini, Miriam Dellino, Eliano Cascardi, Gerardo Cazzato, Antonio Malvasi, Domenico Baldini, Giuseppe Trojano

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Giorgio Maria BaldiniIVF Center, Momo Fertilife, 76011 Bisceglie, Italy.ORCID 0000-0002-5061-8007
Antonella MastroroccoDepartment of Bioscience Biotechnologies and Environment, University of Bari "Aldo Moro", 70125 Bari, Italy.ORCID 0000-0001-7136-4029
Romualdo SciorioEdinburgh Assisted Conception Programme, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK.ORCID 0000-0002-7698-8823
Simone PaliniDepartment of IVF, "San Giorgio" Hospital-AUSL Romagna, 47841 Cervia, Italy.ORCID 0000-0002-2445-6518
Miriam DellinoObstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy.ORCID 0000-0003-3522-4648
Eliano CascardiDepartment of Medical Sciences, University of Turin, 10124 Turin, Italy.ORCID 0000-0003-1287-4285
Gerardo CazzatoSection of Molecular Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-0325-4316
Antonio MalvasiObstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy.
Domenico BaldiniIVF Center, Momo Fertilife, 76011 Bisceglie, Italy.ORCID 0000-0003-1433-504X
Giuseppe TrojanoDepartment of Maternal and Child Health, Madonna delle Grazie Hospital, 75100 Matera, Italy.
University of Bari Aldo Moro · ITOspedale degli Infermi · ITCandiolo Cancer Institute · ITEdinburgh Royal Infirmary · GBOspedale Madonna Delle Grazie · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follitropin delta (Δ) is a recombinant human follicle-stimulating hormone (rFSH), like natural human FSH, that can stimulate the development and growth of multiple follicles. Treatment with Follitropin-Δ may cause mild to severe adverse reactions, such as the risk of developing ovarian hyperstimulation syndrome, resulting in nausea, vomiting and diarrhea, weight loss, respiratory difficulty, stomach swelling and discomfort of the pelvic area, headaches, and fatigue. To date, the effects of a Follitropin-Δ overdosage are unknown, and no data are reported in the scientific literature or in the drug data sheet. Therefore, this study aimed to describe the effects of Follitropin-Δ overdosages in poorly responding women who underwent IVF cycles. This is a descriptive case series of four nulligravid, poorly responding patients, two of whom made requests for fertility preservation. Four poorly responding patients who were prescribed 20.0 µg/day of Follitropin-Δ for three consecutive days wrongly injected the total cartridge of 72 µg Follitropin-Δ every day. After the incorrect injection of Follitropin-Δ, the patients continued their controlled ovarian stimulation and underwent vaginal ovarian pick up. The analyzed patients had no side effects or adverse reactions. The evaluations reported in this case series showed that the accidental use of 72 µg/day of Follitropin-Δ for three days did not cause side effects or adverse reactions in poor responders.

Indexed as

Follitropin delta (Follitropin-Δ)Follitropin delta overdoseside effects of FSH

Identifiers

PMID37629245
PMCPMC10456029
OpenAlexW4385737201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.